BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, has appointed Michael Miller to its Board of Directors. Michael brings multiple decades of strategic leadership and commercial growth experience in the pharmaceutical industry, having most recently served as Executive Vice President, U.S. Commercial at Jazz Pharmaceuticals. Michael led a 450+ person commercial team that generated $2.3 billion in revenues in 2020.
Prior to Jazz, he served in senior executive management positions with commercial, marketing, market access, and sales responsibilities at VIVUS, Genentech (until acquisition by Roche), Connetics Corporation, and ALZA Corporation.
Michael holds a B.S. in Finance from the University of San Francisco and an M.B.A. from San Francisco State University.
See Full Press Release here: https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-appoints-michael-p-miller-board-directors
